| Publication Information (EuropePMC) | |
| Title | Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report. |
| PubMed ID | 37459583(Europe PMC) |
| doi | 10.1200/jco.23.00428 |
| Publication Date | July 17, 2023 |
| Journal | J Clin Oncol |
| Author(s) | Im C, Sharafeldin N, Yuan Y, Wang Z, Sapkota Y, Lu Z, Spector LG, Howell RM, Arnold MA, Hudson MM, Ness KK, Robison LL, Bhatia S, Armstrong GT, Neglia JP, Yasui Y, Turcotte LM. |
| Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
|---|---|---|---|---|---|---|
| PGS000356 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Any cancer | cancer | 179 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000356/ScoringFiles/PGS000356.txt.gz |
|
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|---|
| PPM021339 | PGS000356 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608) |
PSS011694| European Ancestry| 4,322 individuals |
PGP000635 | Im C et al. J Clin Oncol (2023) |Ext. |
Reported Trait: Subsequent malignant neoplasm in nonirridated childhood cancer survivors | HR: 1.28 [1.13, 1.45] | — | — | Sex, age at diagnosis, 5 PCs, study cohort, treatment, and doses of alkylating agents, anthracyclines, epipodophyllotoxins, and platinums | — |
| PPM021337 | PGS000356 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608) |
PSS011696| European Ancestry| 9,895 individuals |
PGP000635 | Im C et al. J Clin Oncol (2023) |Ext. |
Reported Trait: Subsequent malignant neoplasm in childhood cancer survivors | HR: 1.11 [1.05, 1.17] | — | — | Sex, age at diagnosis, 5 PCs, radiation therapy and chemotherapy dosages, cohort/batch effects | — |
| PPM021338 | PGS000356 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608) |
PSS011695| African Ancestry| 718 individuals |
PGP000635 | Im C et al. J Clin Oncol (2023) |Ext. |
Reported Trait: Subsequent malignant neoplasm in childhood cancer survivors | HR: 1.01 [0.66, 1.55] | — | — | Sex, age at diagnosis, 5 PCs, radiation therapy and chemotherapy dosages, cohort/batch effects | — |
| PPM021340 | PGS000356 (PRSWEB_PHECODE10001_UKBB-SAIGE-HRC-X10001_LASSOSUM_MGI_20200608) |
PSS011693| African Ancestry| 414 individuals |
PGP000635 | Im C et al. J Clin Oncol (2023) |Ext. |
Reported Trait: Subsequent malignant neoplasm in nonirridated childhood cancer survivors | HR: 0.86 [0.35, 2.13] | — | — | Sex, age at diagnosis, 5 PCs, study cohort, treatment, and doses of alkylating agents, anthracyclines, epipodophyllotoxins, and platinums | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS011694 | — | — | [
|
— | European | — | CCSS, SJLIFE | — |
| PSS011695 | — | — | 718 individuals, 49.4 % Male samples |
— | African unspecified | — | CCSS, SJLIFE | — |
| PSS011696 | — | — | 9,895 individuals, 49.8 % Male samples |
— | European | — | CCSS, SJLIFE | — |
| PSS011693 | — | — | [
|
— | African unspecified | — | CCSS, SJLIFE | — |